A randomized, double-blind, placebo-controlled trial to assess the efficacy of topiramate in the treatment of post-traumatic stress disorder

Página do item simplificado
dc.contributor.authorMello, Marcelo Feijó de [UNIFESP]
dc.contributor.authorYeh, Mary Sau Ling [UNIFESP]
dc.contributor.authorBarbosa Neto, Jair [UNIFESP]
dc.contributor.authorBraga, Luciana Lorens [UNIFESP]
dc.contributor.authorFiks, Jose Paulo [UNIFESP]
dc.contributor.authorMendes, Deise Daniela [UNIFESP]
dc.contributor.authorMoriyama, Tais Silveira [UNIFESP]
dc.contributor.authorValente, Nina Leao Marques [UNIFESP]
dc.contributor.authorCosta, Mariana Caddrobi Pupo [UNIFESP]
dc.contributor.authorMattos, Patricia [UNIFESP]
dc.contributor.authorBressan, Rodrigo Affonseca [UNIFESP]
dc.contributor.authorAndreoli, Sergio Baxter [UNIFESP]
dc.contributor.authorMari, Jair de Jesus [UNIFESP]
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2016-01-24T13:52:33Z
dc.date.available2016-01-24T13:52:33Z
dc.date.issued2009-05-29
dc.description.abstractBackground: Topiramate might be effective in the treatment of posttraumatic stress disorder (PTSD) because of its antikindling effect and its action in both inhibitory and excitatory neurotransmitters. Open-label studies and few controlled trials have suggested that this anticonvulsant may have therapeutic potential in PTSD. This 12-week randomized, double-blind, placebo-controlled clinical trial will compare the efficacy of topiramate with placebo and study the tolerability of topiramate in the treatment of PTSD.Methods and design: Seventy-two adult outpatients with DSM-IV-diagnosed PTSD will be recruited from the violence program of Federal University of São Paulo Hospital (UNIFESP). After informed consent, screening, and a one week period of wash out, subjects will be randomized to either placebo or topiramate for 12 weeks. the primary efficacy endpoint will be the change in the Clinician-administered PTSD scale (CAPS) total score from baseline to the final visit at 12 weeks.Discussion: the development of treatments for PTSD is challenging due to the complexity of the symptoms and psychiatric comorbidities. the selective serotonin reuptake inhibitors (SSRIs) are the mainstream treatment for PTSD, but many patients do not have a satisfactory response to antidepressants. Although there are limited clinical studies available to assess the efficacy of topiramate for PTSD, the findings of prior trials suggest this anticonvulsant may be promising in the management of these patients.en
dc.description.affiliationUniversidade Federal de São Paulo, Dept Psychiat, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Dept Psychiat, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Dept Psychiat, São Paulo, Brazil
dc.description.provenanceMade available in DSpace on 2016-01-24T13:52:33Z (GMT). No. of bitstreams: 0 Previous issue date: 2009-05-29. Added 1 bitstream(s) on 2016-01-31T13:34:08Z : No. of bitstreams: 1 WOS000268083100002.pdf: 268190 bytes, checksum: 62202584a7a40108b1ef3a8a898a3cdd (MD5)en
dc.description.sourceWeb of Science
dc.format.extent7
dc.identifierhttps://dx.doi.org/10.1186/1471-244X-9-28
dc.identifier.citationBmc Psychiatry. London: Biomed Central Ltd, v. 9, 7 p., 2009.
dc.identifier.doi10.1186/1471-244X-9-28
dc.identifier.fileWOS000268083100002.pdf
dc.identifier.issn1471-244X
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/31528
dc.identifier.wosWOS:000268083100002
dc.language.isoeng
dc.publisherBiomed Central Ltd
dc.relation.ispartofBmc Psychiatry
dc.rightsAcesso aberto
dc.titleA randomized, double-blind, placebo-controlled trial to assess the efficacy of topiramate in the treatment of post-traumatic stress disorderen
dc.typeArtigo
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
WOS000268083100002.pdf
Tamanho:
261.9 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Coleções
EPM - Artigos